Strategic Signals Weekly
Licensing deals, strategic reviews, and financing events from regulatory filings. Part of the RxDataLab platform: clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Delivery
Get next week's Strategic Signals Weekly by email
One email per week. We follow up on coverage that's relevant to you.
or email [email protected]
Weekly Signal Volume
FDA Actions (CRL)
Companies that received a Complete Response Letter from the FDA, indicating a drug application was not approved in its current form.
| Filed | Company |
|---|---|
| Feb 27 | Disc Medicine, Inc. (IRON) ...strategic priorities following the receipt of a complete response letter from the U.S. Food and Drug Administration ("FDA") on February 13, 2026 with respect to the Company's New Drug Application for bitopertin for the treatment of erythropoietic protoporphyria and...
[SEC] |
Strategic Reviews
Companies exploring strategic alternatives, potential M&A, or board-level reviews.
| Filed | Company |
|---|---|
| Feb 24 | Werewolf Therapeutics, Inc. (HOWL) ...release announcing that it plans to explore strategic alternatives and has engaged Piper Sandler & Co. as its exclusive financial advisor to assist in the strategic evaluation. A copy of the press release is furnished as Exhibit 99....
[SEC] |
| Feb 23 | Genprex, Inc. (GNPX) ...prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including...
[SEC] |
Licensing & Partnerships
New collaboration agreements, licensing deals, and partnership announcements.
| Filed | Company |
|---|---|
| Feb 23 | Vir Biotechnology, Inc. (VIR) ...Astellas) entered into a Collaboration and License Agreement (the Agreement). Upon closing of the transaction contemplated by the Agreement (the Closing and the Transaction, respectively), Vir Bio and Astellas will enter into a global strategic collaboration...
[SEC] |
Financing Events
Capital raises, ATM programs, debt offerings, and other financing activities.
| Filed | Company |
|---|---|
| Feb 27 | Larimar Therapeutics, Inc. (LRMR) $107.6M
public offering
[SEC] |
| Feb 27 | Xenon Pharmaceuticals Inc. (XENE) atm
[SEC] |
| Feb 27 | TANDEM DIABETES CARE INC (TNDM) $290.7M
private placement
[SEC] |
| Feb 26 | Kymera Therapeutics, Inc. (KYMR) atm
[SEC] |
| Feb 26 | Zura Bio Ltd (ZURA) $134.6M
public offering
[SEC] |
| 9 more on the RxDataLab platform | |
About This Data
These events are extracted from SEC 8-K filings using keyword detection across the full filing text. Summaries are generated automatically from the filing content to describe what happened in plain language. We track five categories:
- FDA Actions (CRL): Companies that received a Complete Response Letter from the FDA, the agency's formal notice that a drug application cannot be approved as submitted.
- PDUFA Dates: Upcoming FDA decision deadlines disclosed via 8-K. A PDUFA date is the statutory deadline by which the FDA must complete its review of a new drug application.
- Strategic Reviews: Companies disclosing that they are exploring "strategic alternatives," potential sales, or board-level reviews of company direction.
- Licensing Deals: Material definitive agreements involving licensing, collaboration, or partnership arrangements. Requires multiple keyword matches to reduce noise.
- Financing Events: Capital raises, ATM offerings, registered direct transactions, and debt issuances. Filing proceeds are extracted where disclosed.
On the RxDataLab platform, each event is cross-referenced with the company's clinical trial pipeline, insider trading activity, and financials.
Data from RxDataLab and SEC EDGAR.